RESIDUAL ANTIFACTOR-XA WITHOUT ELEVATED ACTIVATED PARTIAL THROMBOPLASTIN TIME AFTER REPEATED DAILY DOSING WITH A LOW-MOLECULAR WEIGHT HEPARIN, FRAXIPARINE

被引：0
|
作者：
FREEDMAN, MD
PRASAD, R
LEESE, P
HAYDEN, D
机构：
[1] SANOFI RES,NEW YORK,NY
[2] QUINCY RES CTR,KANSAS CITY,MO
来源：
THROMBOSIS AND HAEMOSTASIS | 1989年 / 62卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：526 / 526
页数：1
相关论文
共 16 条
  • [1] AMIDOLYTIC ANTIFACTOR-XA ASSAYS IN THE LABORATORY EVALUATION OF HEPARIN AND LOW-MOLECULAR WEIGHT FRACTIONS
    WALENGA, JM
    BARA, L
    SAMAMA, MM
    FAREED, J
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1985, 11 (02): : 100 - 107
  • [2] PARTIAL THROMBOPLASTIN TIME, ANTI-XA, AND LOW-MOLECULAR WEIGHT HEPARIN ADMINISTRATION
    FREEDMAN, MD
    HAYDEN, D
    PRASAD, R
    LEESE, PT
    CLINICAL RESEARCH, 1989, 37 (01): : A103 - A103
  • [3] Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
    McLaughlin, Kevin
    Rimsans, Jessica
    Sylvester, Katelyn W.
    Fanikos, John
    Dorfman, David M.
    Senna, Patricia
    Connors, Jean M.
    Goldhaber, Samuel Z.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
  • [4] Low molecular weight heparin and activated partial thromboplastin time
    Castellone, DD
    Peerschke, EIB
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1999, 112 (04) : 567 - 568
  • [5] Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis
    Swayngim, Rebecca
    Preslaski, Candice
    Burlew, Clay Cothren
    Beyer, Jacob
    THROMBOSIS RESEARCH, 2021, 208 : 18 - 25
  • [6] Correlation between activated partial thromboplastin time and anti-Xa activity in patients who received low-molecular weight heparin as anticoagulation for haemodialysis
    Wong, Steve Siu-Man
    Lau, Wai-Yan
    Chan, Ping-Kwan
    Wan, Ching-Kit
    Cheng, Yuk-Lun
    NEPHROLOGY, 2017, 22 (11) : 921 - 924
  • [7] Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study
    Rizk, Elsie
    Wilson, Allison D.
    Murillo, Michelle U.
    Putney, David R.
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 151 - 155
  • [8] Anti-factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation
    Feng, Iris
    Kurlansky, Paul A.
    Powley, Tanner R.
    Hynds, Melissa A.
    Yang, Christine G.
    Eisenberger, Andrew
    Hastie, Jonathan M.
    Sutherland, Lauren D.
    Yuzefpolskaya, Melana
    Colombo, Paolo C.
    Sayer, Gabriel T.
    Uriel, Nir Y.
    Naka, Yoshifumi
    Takeda, Koji
    ARTIFICIAL ORGANS, 2024,
  • [9] Anti-Factor Xa and Activated Partial Thromboplastin Time Strategies for Heparin Dosing After HeartMate3 Left Ventricular Assist Device Implantation
    Feng, I.
    Kurlansky, P. A.
    Powley, T. R.
    Vinogradsky, A. V.
    Hynds, M. A.
    Yang, C. G.
    Hastie, J. M.
    Sutherland, L. D.
    Shih, H.
    Yuzefpolskaya, M.
    Colombo, P. C.
    Sayer, G. T.
    Naka, Y.
    Uriel, N.
    Takeda, K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S389 - S389
  • [10] Prothrombin time, activated partial thromboplastin time and low molecular weight heparin testing practices in a survey of 800 randomly selected US hospitals.
    Shahangian, S
    Stankovic, AK
    Lubin, IM
    Handsfield, JH
    White, MD
    CLINICAL CHEMISTRY, 2003, 49 (06) : A4 - A4
12